But before we go jumping the gun on if and when a CR is needed or not, I would like to see what happens with the following first
1. Interim Vax results
2. Possible partnership after vax if results are generally regarded as positive
3. Revenue of CC sales and costs reductions over this quarter and the next.
Absolutely, and perhaps another avenue to escape a CR...
4. CC partnership in China, or elsewhere, with upfront partnership fees
Even with just organic growth of CC sales and controlled costs, the cash runway could increase significantly, possibly up to 12-18 months which would give plenty of time for partnerships to materialise.
Exee
But before we go jumping the gun on if and when a CR is needed...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.15 |
Change
0.000(0.00%) |
Mkt cap ! $291.2M | |||
| Open | High | Low | Value | Volume |
| $15.00 | $15.15 | $14.60 | $347.8K | 23.20K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 760 | $15.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.15 | 388 | 1 |
View Market Depth
| Last trade - 15.58pm 30/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |